Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Glastonbury is as popular than ever, but complaints about the lineup reveal its generational challenge 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
AI is driving down the price of knowledge – universities have to rethink what they offer 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
